Gaush Meditech Ltd (HKG:2407)
Hong Kong · Delayed Price · Currency is HKD 4.585
-0.105 (-2.24%)
Sep 11, 2026, 3:50 PM HKT
Gaush Meditech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,322 | 1,380 | 1,428 | 1,406 | 1,254 | 1,298 | |
Revenue Growth | -8.13% | -3.36% | 1.58% | 12.16% | -3.42% | 34.94% |
Cost of Revenue | 724.85 | 755.48 | 774.43 | 721.64 | 632.54 | 696.61 |
Gross Profit | 597.57 | 624.87 | 653.96 | 684.6 | 621.25 | 601.61 |
Selling, General & Admin | 420.9 | 418.98 | 378.36 | 378.21 | 333.94 | 320.99 |
Research & Development | 91.4 | 92.58 | 78.42 | 52.88 | 41.09 | 23.51 |
Other Operating Expenses | -1.3 | 0.71 | 2.64 | 0.2 | 19.19 | 13.8 |
Operating Expenses | 510.99 | 512.26 | 459.42 | 431.3 | 394.21 | 358.3 |
Operating Income | 86.58 | 112.61 | 194.55 | 253.3 | 227.03 | 243.32 |
Interest Expense | -15.5 | -19.59 | -36.71 | -50.61 | -42.68 | -83.53 |
Interest & Investment Income | 2.46 | 2.46 | 3.18 | 6.58 | 4.68 | 2.02 |
Currency Exchange Gain (Loss) | -15.11 | -6.35 | -5.71 | 15.56 | -172.47 | 61.82 |
Other Non Operating Income (Expenses) | 25.16 | 24.47 | 19.52 | 18.8 | 16.43 | 13.97 |
EBT Excluding Unusual Items | 83.58 | 113.6 | 174.82 | 243.63 | 32.99 | 237.6 |
Impairment of Goodwill | -2.36 | -2.36 | -23.26 | - | - | - |
Gain (Loss) on Sale of Investments | 2.81 | 2.81 | 3.72 | 3.96 | -307.42 | -375.51 |
Gain (Loss) on Sale of Assets | - | - | - | 0.15 | -0.67 | -0.05 |
Other Unusual Items | 0.64 | 0.64 | - | - | - | - |
Pretax Income | 84.66 | 114.68 | 155.29 | 247.74 | -275.09 | -137.96 |
Income Tax Expense | 14.3 | 23.49 | 66.76 | 74.82 | 77.62 | 53.61 |
Earnings From Continuing Operations | 70.36 | 91.19 | 88.52 | 172.91 | -352.71 | -191.57 |
Minority Interest in Earnings | 5.13 | 5 | 3.87 | 0.61 | 3.09 | 1.12 |
Net Income | 75.49 | 96.19 | 92.39 | 173.52 | -349.62 | -190.45 |
Net Income to Common | 75.49 | 96.19 | 92.39 | 173.52 | -349.62 | -190.45 |
Net Income Growth | -25.92% | 4.11% | -46.75% | - | - | - |
Shares Outstanding (Basic) | 144 | 145 | 148 | 148 | 97 | 96 |
Shares Outstanding (Diluted) | 144 | 145 | 148 | 148 | 97 | 96 |
Shares Change | -2.21% | -1.83% | -0.14% | 52.69% | 1.16% | -9.03% |
EPS (Basic) | 0.53 | 0.66 | 0.63 | 1.17 | -3.61 | -1.99 |
EPS (Diluted) | 0.53 | 0.66 | 0.63 | 1.17 | -3.61 | -1.99 |
EPS Growth | -24.24% | 6.05% | -46.68% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 121.46 | 93.12 | 214.11 | 189.03 | 137.94 |
Free Cash Flow Per Share | - | 0.84 | 0.63 | 1.45 | 1.95 | 1.44 |
Dividend Per Share | - | - | 0.282 | 0.998 | - | - |
Dividend Growth | - | - | -71.77% | - | - | - |
Gross Margin | 45.19% | 45.27% | 45.78% | 48.68% | 49.55% | 46.34% |
Operating Margin | 6.55% | 8.16% | 13.62% | 18.01% | 18.11% | 18.74% |
Profit Margin | 5.71% | 6.97% | 6.47% | 12.34% | -27.88% | -14.67% |
Free Cash Flow Margin | - | 8.80% | 6.52% | 15.23% | 15.08% | 10.63% |
EBITDA | 152.1 | 177.75 | 251.65 | 306.06 | 271.91 | 287.2 |
EBITDA Margin | 11.50% | 12.88% | 17.62% | 21.77% | 21.69% | 22.12% |
D&A For EBITDA | 65.52 | 65.14 | 57.1 | 52.76 | 44.87 | 43.88 |
EBIT | 86.58 | 112.61 | 194.55 | 253.3 | 227.03 | 243.32 |
EBIT Margin | 6.55% | 8.16% | 13.62% | 18.01% | 18.11% | 18.74% |
Effective Tax Rate | 16.89% | 20.48% | 42.99% | 30.20% | - | - |